NATCOPHARM2020-04-012020-06-30in-bse-fin:OneOperatingExpenses01Member NATCOPHARM2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NATCOPHARM2020-04-012020-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NATCOPHARM 2020-04-01 2021-03-31 2020-08-03 INR Millions First quarter Single segment Pharmaceutical 2020-04-01 2020-06-30 Unaudited Standalone 5322000000.00 199000000.00 5521000000.00 1214000000.00 433000000.00 97000000.00 900000000.00 33000000.00 276000000.00 952000000.00 3905000000.00 1616000000.00 0.00 1616000000.00 414000000.00 -65000000.00 349000000.00 0.00 1267000000.00 0.00 0.00 0.00 0.00 1267000000.00 5000000.00 1272000000.00 1272000000.00 0.00 364000000.00 2 6.96 6.94 0.00 0.00 6.96 6.94 Where financial results contain both consolidated and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment in formation has been presented in the consolidated financial results. Others 952000000.00